Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
OncoTherapy Science, Inc. is a Japanese biotechnology firm dedicated to the discovery and advancement of innovative cancer treatments. Established in 2001 and headquartered in Kawasaki, Japan, the company's robust pipeline spans various therapeutic modalities. Among its small-molecule compounds, OTS167, an inhibitor of maternal embryonic leucine zipper kinase, is undergoing Phase I/II clinical trials for acute myeloid leukemia and Phase I trials for breast cancer. Another small-molecule asset, OTS964, targets T-LAK cell-originated protein kinase for a range of oncological conditions. The company's oncology peptide vaccine candidates include S-588410, which is in Phase III trials for esophageal cancer and Phase II for bladder cancer. S-488210 is progressing through Phase I/II clinical trials for head and neck cancer, while S-588210 is in Phase I for solid malignancies. In its antibody drug portfolio, OTSA101 is in Phase I clinical trials for synovial sarcoma. Notably, KHK6640, an anti-amyloid beta peptide antibody, is also in Phase I trials, targeting Alzheimer's disease – indicating a broader therapeutic scope. Beyond drug development, OncoTherapy Science, Inc. also provides specialized contract analysis services.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.